A product sold as a “GLP-1 patch” borrows the name of a drug class it does not contain. The patches on sale are marketed as dietary supplements built from plant extracts and amino acids, not as semaglutide or tirzepatide, and no patch form of any GLP-1 drug carries FDA approval. What the receptor does, and why the prescription drugs work on it, is covered in the mechanism article; this page is about what happens when the same name is put on something worn on the skin.
What is printed on the label
A 2026 survey from the University of Connecticut School of Pharmacy identified 24 transdermal patch products and one transdermal gel marketed as “natural GLP-1” dietary supplements. They listed an average of 7 ± 4 natural ingredients, with berberine, glutamine or glutamate, cinnamon and pomegranate appearing most often.[1]
None of those is a GLP-1 receptor agonist. Several are sold elsewhere as capsules, and what the swallowed versions have and have not shown is set out in the article on GLP-1 supplements and berberine. The same survey found that no product posted a certificate of analysis, that many lacked the FDA disclaimer supplements are required to carry, and that many used deceptive advertising. Several carried one- and two-star ratings with consumer comments describing no effect or adverse events.[1]
A patch cannot legally be a dietary supplement
The federal definition of a dietary supplement is built around ingestion: it points to products “intended for ingestion”, in the first instance in tablet, capsule, powder, softgel, gelcap or liquid form.[2] The FDA states the consequence plainly: dietary supplements are products that are ingested, and topical or inhaled products are not supplements.[3] On that basis the survey authors concluded that every transdermal “natural GLP-1” product they found is illegal as marketed.[1]
The supplement label would not have meant much even if it applied. Under the Dietary Supplement Health and Education Act the FDA has no authority to approve dietary supplements, or their labeling, before they are sold.[3] The difference between a product nobody reviewed and an approved drug is laid out in what “not FDA-approved” actually means.
The skin barrier, measured in daltons
The outer layer of skin, the stratum corneum, keeps most molecules out. A widely cited 2000 review in Experimental Dermatology argued that a compound must weigh under about 500 daltons to be absorbed through intact skin. Its evidence was that virtually all common contact allergens fall below that size, and that every drug then used in a transdermal delivery system did as well.[4]
The prescription GLP-1 drugs are an order of magnitude past it. The Wegovy label gives semaglutide a molecular weight of 4,113.58 g/mol, roughly eight times the threshold.[5] The Zepbound label gives tirzepatide 4,813.53 Da, close to ten times it.[6] A sticker containing either peptide, pressed against unbroken skin, would not be expected to deliver a meaningful dose.
Even the gut absorbs almost none of it
Size is why every approved route either bypasses a barrier or works hard to get around one. Injected under the skin, semaglutide reaches the bloodstream with an absolute bioavailability of 89%, and tirzepatide with 80%.[5][6]
The oral tablet shows how hard the alternative is. Rybelsus pairs semaglutide with an absorption enhancer, SNAC, and still achieves an estimated absolute bioavailability of only 0.4% to 1%.[7] That is why the Wegovy tablet is dosed at 25 mg once daily while the injection is 2.4 mg once weekly.[5] A route engineered specifically for this molecule absorbs around one percent of it; the trials behind the tablet are in the oral-versus-injectable article.
The research that does work pierces the skin
Transdermal GLP-1 delivery is a real research field, and its results are the part most easily misread. Nearly all of it uses microneedles: arrays of tiny projections that physically breach the stratum corneum, then dissolve or release drug into the layer beneath. A microneedle patch is, functionally, a small injection.
The published results are early and almost entirely preclinical. A 2014 study of dissolving hyaluronate microneedles loaded with exenatide reported release within 2 minutes of insertion, skin-barrier recovery within 10 to 12 hours, and antidiabetic effects comparable to a subcutaneous injection.[8] A 2025 study of semaglutide in aminoclay-hyaluronic acid microneedles reported efficacy comparable to injection in type 2 diabetic rats.[9]
One 2025 mouse study went further, reporting that transdermal semaglutide produced greater weight loss than injected semaglutide in male mice.[10] A 2024 design packed four core-shell microneedle “pixels” into a 2 cm by 2 cm patch meant to release semaglutide every 7 days for a month; the corresponding author disclosed a patent application on the platform.[11]
That reads like support for the patches on sale, and it is the reverse. Every positive result came from a device that punctures the skin, carrying the actual peptide, tested in animals. A 2026 microneedle study that got no further than excised pig skin noted that loss of therapeutic activity and peptide stability remain unresolved challenges.[12] A 2024 osmotic microneedle patch did reach people, but its human participants assessed comfort and skin irritation; its exenatide dosing was measured in rats and mice.[13]
None of these devices is approved, and none contains berberine or cinnamon. A product that adheres to the skin without needles and lists no GLP-1 drug shares nothing with this literature except the word “patch”.
What the FTC has said about worn weight-loss products
The Federal Trade Commission’s guide for media outlets screening weight-loss advertising lists seven claims it treats as false on their face. One is that a product causes substantial weight loss by being worn on the body or rubbed into the skin. The guide’s reasoning is that weight loss is an internal metabolic process, and it names patches, creams, lotions and wraps among the products whose weight-loss claims are false.[14]
That guidance predates the GLP-1 marketing wave by a decade, and it applies to these products without modification. How the substantiation rules reach GLP-1 advertising more broadly is in the advertising rules article. Separately, the FDA has warned consumers against semaglutide, tirzepatide and investigational peptides sold online labeled “for research purposes” or “not for human consumption”.[15] What testing has found inside fake injectables is in the counterfeit article.
What an approved route looks like
Every approved form of semaglutide or tirzepatide on a current label is a subcutaneous injection or, for semaglutide, an oral tablet taken on a strict schedule.[5][6][7] Each requires a prescription, and each label lists contraindications, including a personal or family history of medullary thyroid carcinoma, that a prescriber is meant to screen for.
Many cash-pay telehealth services dispense compounded semaglutide or tirzepatide instead of the branded product. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed; the trade-offs are set out in the compounded-versus-brand article. For a reader who wants to avoid needles, sellers prescribing the tablet are collected on the oral semaglutide board, and the patterns that separate a real prescribing service from a storefront are in the telehealth red flags article.
Reading a patch listing in thirty seconds
Three things on a product page settle most of the question. The first is whether a drug is named at all: an approved GLP-1 product states an active ingredient and a strength in milligrams, such as semaglutide 2.4 mg, and a patch listing that names only extracts and amino acids is not selling one.[1] The second is whether a prescription is required. Every approved semaglutide and tirzepatide product is prescription-only, so a checkout that asks for nothing but a card is selling something else.
The third is the language around the word itself. Phrases such as “GLP-1 support”, “natural GLP-1” or “GLP-1 boosting” describe a hoped-for effect on the body’s own hormone, not the presence of a drug, and the 2026 survey found many listings using advertising its authors classed as deceptive.[1] A missing “not evaluated by the Food and Drug Administration” disclaimer, which the FDA requires on supplement claims of this kind, is a further signal that nobody checked the label against the rules.[3]
What none of this decides
Nothing above shows that the botanicals in these patches are harmful, and nothing shows they work through the skin either; neither question has a published trial behind it. What is established is narrower and firmer: the products are not GLP-1 drugs, they do not meet the legal definition of the category they are sold under, and the molecule they are named after is far too large to cross intact skin. A microneedle GLP-1 patch may one day reach a label. If it does, it will arrive through a prescription, not a supplement checkout.